Home >> Research Area >> Tobramycin Sulfate

Tobramycin Sulfate

CAS# 49842-07-1

Tobramycin Sulfate

Catalog No. BCC5633----Order now to get a substantial discount!

Product Name & Size Price Stock
Tobramycin Sulfate: 5mg $12 In Stock
Tobramycin Sulfate: 10mg Please Inquire In Stock
Tobramycin Sulfate: 20mg Please Inquire Please Inquire
Tobramycin Sulfate: 50mg Please Inquire Please Inquire
Tobramycin Sulfate: 100mg Please Inquire Please Inquire
Tobramycin Sulfate: 200mg Please Inquire Please Inquire
Tobramycin Sulfate: 500mg Please Inquire Please Inquire
Tobramycin Sulfate: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of Tobramycin Sulfate

Number of papers citing our products

Chemical structure

Tobramycin Sulfate

3D structure

Chemical Properties of Tobramycin Sulfate

Cas No. 49842-07-1 SDF Download SDF
PubChem ID 62005 Appearance Powder
Formula C18H39N5O13S M.Wt 565.59
Type of Compound N/A Storage Desiccate at -20°C
Solubility <5.66mg/mL in DMSO
Chemical Name (2S,3R,4S,5S,6R)-4-amino-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,5S,6R)-3-amino-6-(aminomethyl)-5-hydroxyoxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol;sulfuric acid
SMILES C1C(C(C(C(C1N)OC2C(C(C(C(O2)CO)O)N)O)O)OC3C(CC(C(O3)CN)O)N)N.OS(=O)(=O)O
Standard InChIKey ZEUUPKVZFKBXPW-TWDWGCDDSA-N
Standard InChI InChI=1S/C18H37N5O9.H2O4S/c19-3-9-8(25)2-7(22)17(29-9)31-15-5(20)1-6(21)16(14(15)28)32-18-13(27)11(23)12(26)10(4-24)30-18;1-5(2,3)4/h5-18,24-28H,1-4,19-23H2;(H2,1,2,3,4)/t5-,6+,7+,8-,9+,10+,11-,12+,13+,14-,15+,16-,17+,18+;/m0./s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Tobramycin Sulfate Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Tobramycin Sulfate Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Tobramycin Sulfate

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 1.7681 mL 8.8403 mL 17.6807 mL 35.3613 mL 44.2016 mL
5 mM 0.3536 mL 1.7681 mL 3.5361 mL 7.0723 mL 8.8403 mL
10 mM 0.1768 mL 0.884 mL 1.7681 mL 3.5361 mL 4.4202 mL
50 mM 0.0354 mL 0.1768 mL 0.3536 mL 0.7072 mL 0.884 mL
100 mM 0.0177 mL 0.0884 mL 0.1768 mL 0.3536 mL 0.442 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University
Featured Products
New Products
 

References on Tobramycin Sulfate

Clinical application of tobramycin-impregnated calcium sulfate beads in six dogs (2002-2004).[Pubmed:18981197]

J Am Anim Hosp Assoc. 2008 Nov-Dec;44(6):320-6.

Medical records for six dogs treated with tobramycin-impregnated calcium sulfate beads were reviewed for indications, duration of disease, number of beads implanted, complications, radiographic appearance of the beads, and outcomes. Beads were no longer visible on radiographs made 5 weeks after implantation. Osteomyelitis resolved in five of five dogs with follow-up. The lack of complications and the resolution of clinical signs associated with tobramycin calcium sulfate bead implantation support their clinical application in treating osteomyelitis.

Purity determination of amphotericin B, colistin sulfate and tobramycin sulfate in a hydrophilic suspension by HPLC.[Pubmed:25828728]

J Chromatogr B Analyt Technol Biomed Life Sci. 2015 May 15;990:7-14.

A suspension comprising of the three antibiotic substances amphotericin B, colistin sulfate and Tobramycin Sulfate is often used in clinical practice for the selective decontamination of the digestive tract of patients in intensive care. Since no detailed procedures, specifications or stability data are available for manufacturing this suspension, there may be discrepancies regarding formulation and stability of suspensions prepared in different pharmacies. The aim of this work is to develop a standardized formulation and to determine its stability under defined storage conditions. This would help guarantee that all patients receive the same preparation, therefore ensuring similar efficacy and improved safety. The first step in this process is to develop the required analytical tools to measure the content and purity of the drug substances in this complex mixture. In this paper, the development and validation of these tools as well as the development of the drug suspension formulation is described. The formulation comprises of Ampho-Moronal((R))-Suspension (Dermapharm) and a buffered, preservated aqueous solution of colistin sulfate and Tobramycin Sulfate. Two simple, well established high-performance liquid chromatography (HPLC) methods in the European Pharmacopoeia (EP) for impurity profiling of the two active ingredients amphotericin B and colistin sulfate were combined with a newly developed sample extraction procedure for the suspension. Sufficient selectivity and stability-indicating power have been demonstrated. Additionally, a new robust routine method was developed to determine possible degradation products of Tobramycin Sulfate in the investigated suspension. The specificity, precision, accuracy and linearity of the analytical procedures were demonstrated. The recovery rate was in the range of 90-110%. The precision results for the calculated impurities showed variation coefficients of <10%. The calibration curves were found to be linear with correlation of greater than 0.9994 for all components. The results show the suitability of the methods for the quality control analysis of the suspension.

Tobramycin exposure from active calcium sulfate bone graft substitute.[Pubmed:24593819]

BMC Pharmacol Toxicol. 2014 Mar 4;15:12.

BACKGROUND: Bone graft substitute such as calcium sulfate are frequently used as carrier material for local antimicrobial therapy in orthopedic surgery. This study aimed to assess the systemic absorption and disposition of tobramycin in patients treated with a tobramycin-laden bone graft substitute (Osteoset(R) T). METHODS: Nine blood samples were taken from 12 patients over 10 days after Osteoset(R) T surgical implantation. Tobramycin concentration was measured by fluorescence polarization. Population pharmacokinetic analysis was performed using NONMEM to assess the average value and variability (CV) of pharmacokinetic parameters. Bioavailability (F) was assessed by equating clearance (CL) with creatinine clearance (Cockcroft CLCr). Based on the final model, simulations with various doses and renal function levels were performed. (ClinicalTrials.gov number, NCT01938417). RESULTS: The patients were 52 +/- 20 years old, their mean body weight was 73 +/- 17 kg and their mean CLCr was 119 +/- 55 mL/min. Either 10 g or 20 g Osteoset(R) T with 4% Tobramycin Sulfate was implanted in various sites. Concentration profiles remained low and consistent with absorption rate-limited first-order release, while showing important variability. With CL equated to CLCr, mean absorption rate constant (ka) was 0.06 h-1, F was 63% or 32% (CV 74%) for 10 and 20 g Osteoset(R) T respectively, and volume of distribution (V) was 16.6 L (CV 89%). Simulations predicted sustained high, potentially toxic concentrations with 10 g, 30 g and 50 g Osteoset(R) T for CLCr values below 10, 20 and 30 mL/min, respectively. CONCLUSIONS: Osteoset(R) T does not raise toxicity concerns in subjects without significant renal failure. The risk/benefit ratio might turn unfavorable in case of severe renal failure, even after standard dose implantation.

A Microfluidic Approach to Investigating a Synergistic Effect of Tobramycin and Sodium Dodecyl Sulfate on Pseudomonas aeruginosa Biofilms.[Pubmed:26753708]

Anal Sci. 2016;32(1):67-73.

In recent years, a microfluidic technology has contributed a significant role in biological research, specifically for the study of biofilms. Bacterial biofilms are a source of infections and contamination in the environment due to an extra polymeric matrix. Inadequate uses of antibiotics make the bacterial biofilms antibiotic resistant. Therefore, it is important to determine the effective concentration of antibiotics in order to eliminate bacterial biofilms. The present microfluidic study was carried out to analyze the activities of tobramycin and sodium dodecyl sulfate (SDS) against Pseudomonas aeruginosa biofilms with a continuous flow in order to achieve a greater delivery of the agents. The results show that a co-treatment of tobramycin and SDS significantly reduced the biomass of biofilms (by more than 99%) after 24 h. Tobramycin and SDS killed and detached bacteria in the cores of biofilms. Evidently, our data suggest that a microchannel would be effective for both quantitative and qualitative evaluations in order to test combinatorial effect of drugs and chemicals on a complexed biological system including biofilm.

Description

Tobramycin sulfate (Nebramycin Factor 6 sulfate) is a parenterally administered, broad spectrum aminoglycoside antibiotic that is widely used in the treatment of moderate to severe bacterial infections due to sensitive organisms.

Keywords:

Tobramycin Sulfate,49842-07-1,Natural Products, buy Tobramycin Sulfate , Tobramycin Sulfate supplier , purchase Tobramycin Sulfate , Tobramycin Sulfate cost , Tobramycin Sulfate manufacturer , order Tobramycin Sulfate , high purity Tobramycin Sulfate

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: